Transcode Therapeutics, Inc. current report, 26 July 2023

Full document

TransCode Therapeutics, Inc. — Form 8-K Summary

Business context and reporting period

TransCode Therapeutics, Inc. filed a Form 8-K under Item 3.01 on July 26, 2023, regarding noncompliance with Nasdaq’s continued-listing stockholders’ equity requirement. The report was signed and filed on July 28, 2023. The company’s common stock trades under the symbol RNAZ on the Nasdaq Capital Market.

Financial and liquidity metrics

The filing does not provide revenue, earnings, cash flow, margins, debt, cash balances, or other quantitative financial results. It states that the company does not meet Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market.

Material changes versus the prior comparable period

  • On May 16, 2023, Nasdaq notified the company that it was not compliant with the stockholders’ equity requirement.
  • The company submitted a compliance plan on June 30, 2023, and supplemented it on July 24, 2023.
  • On July 26, 2023, Nasdaq’s Listing Qualifications Department rejected the compliance plan and denied the company’s request for an extension.

Guidance, outlook, risks, contingencies, and unusual items

  • The company intends to request a hearing before the Nasdaq Hearings Panel no later than August 2, 2023.
  • If the company does not request a hearing, its common stock would be suspended from Nasdaq trading at the open of business on August 4, 2023.
  • A timely hearing request would stay Nasdaq’s delisting action at least until the hearing process concludes and any extension granted by the Panel expires.
  • The company plans to present a strategy for regaining compliance, but there is no assurance that the Panel will accept the plan or that the company will regain compliance.
  • Potential risks include suspension or delisting from Nasdaq, an inability to satisfy the stockholders’ equity requirement, and adverse effects on the company’s stock liquidity, financing capacity, and investor base.
  • The filing’s forward-looking statements are subject to the risks described in the company’s Form 10-K for the year ended December 31, 2022, and subsequent SEC filings.

Important facts for investors to verify

  1. Whether the company submitted the intended Nasdaq Hearings Panel request by August 2, 2023.
  2. Whether the hearing request stayed suspension or delisting proceedings.
  3. The company’s current stockholders’ equity and the specific actions proposed to restore compliance.
  4. The Nasdaq Panel’s decision, any extension granted, and the applicable compliance deadline.
  5. Subsequent SEC filings for financing activity, capital structure changes, liquidity updates, and any trading suspension or delisting notice.